OUP user menu

Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders

Hermine Agis MD, Maria-Theresa Krauth MD, Alexandra Böhm MD, Isabella Mosberger, Leonhard Müllauer MD, PhD, Ingrid Simonitsch-Klupp MD, Andrew F. Walls PhD, Hans-Peter Horny MD, Peter Valent MD
DOI: http://dx.doi.org/10.1309/M9FQMQGF66167N2X 273-281 First published online: 1 February 2006


In myeloproliferative disorders (MPDs), basophils typically increase in number in the bone marrow (BM) and blood. In chronic myeloid leukemia (CML), basophilia is a diagnostic and prognostic variable. However, no reliable approach for routine detection and enumeration of basophils in BM sections is available. We applied the antibasogranulin antibody BB1 on paraffin-embedded BM sections in 21 control samples (normal BM), 45 patients with CML, 9 with chronic idiopathic myelofibrosis, 11 with polycythemia vera, 19 with essential thrombocythemia, and 7 with indolent systemic mastocytosis. As assessed by immunostaining of serial BM sections, BB1+ cells coexpressed myeloperoxidase, histidine decarboxylase, and leukosialin but did not express B- or T-cell–restricted antigens. BB1+ BM cells were found to be highly elevated in patients with CML compared with normal BM or other MPDs, with maximum counts found in accelerated phase CML (median, 160 cells/mm2). In summary, BB1 (basogranulin) is a new immunohistochemical basophil marker that should allow quantification of basophils in CML at diagnosis and during therapy.

Key Words:
  • Myeloproliferative disorders
  • Chronic myeloid leukemia
  • CML
  • Basophils
  • Basogranulin